Straits Times Index
3,258.90 +1.72 (+0.05%) Nikkei
28,041.48 +258.55 (+0.93%) Hang Seng
20,400.11 +90.98 (+0.45%) FTSE 100
7,631.74 +11.31 (+0.15%) Bitcoin USD
28,469.86 +14.33 (+0.05%) CMC Crypto 200
621.79 +7.58 (+1.23%)
LLY Apr 2023 360.000 call
| Previous close | 1.4000 |
| Open | 1.5300 |
| Bid | 1.1800 |
| Ask | 1.6000 |
| Strike | 360.00 |
| Expiry date | 2023-04-21 |
| Day's range | 1.2000 - 1.5300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.36k |
- Motley Fool
3 Stocks That Could Benefit From the Ozempic Craze
Ozempic is a drug that has been soaring in popularity over the past year. Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk.
- Motley Fool
3 Dividend Stocks That Have Been Paying Investors Since the 1800s
Three businesses that have not only been around for more than a century but have also been paying dividends going back to the 1800s are Eli Lilly (NYSE: LLY), ExxonMobil (NYSE: XOM), and the Toronto-Dominion Bank (NYSE: TD). Healthcare giant Eli Lilly has been paying a dividend since 1885.
- Reuters
Boehringer's profit up as Jardiance gains offset higher costs
FRANKFURT (Reuters) -German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.
